DOI:
10.1055/s-00000009
American Journal of Perinatology
LinksClose Window
References
Ablynx initiates the phase IIb "respire" study of its wholly-owned, first-in-class, inhaled anti-RSV nanobody, ALX-0171, for the treatment of RSV infections in hospitalised infants.
Available at:
https://www.globenewswire.com/news-release/2017/01/11/905176/0/en/ABLYNX-INITIATES-THE-PHASE-IIb-RESPIRE-STUDY-OF-ITS-WHOLLY-OWNED-FIRST-IN-CLASS-INHALED-ANTI-RSV-NANOBODY-ALX-0171-FOR-THE-TREATMENT-OF-RSV-INFECTIONS-IN-HOSPITALISED-INFANTS.html . Accessed June 7, 2019
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.